scispace - formally typeset
M

Maria Domenica Cappellini

Researcher at University of Milan

Publications -  570
Citations -  21441

Maria Domenica Cappellini is an academic researcher from University of Milan. The author has contributed to research in topics: Thalassemia & Deferasirox. The author has an hindex of 71, co-authored 518 publications receiving 18668 citations. Previous affiliations of Maria Domenica Cappellini include Centra & Vita-Salute San Raffaele University.

Papers
More filters
Journal ArticleDOI

Priapism, an emerging complication in β-thalassemia intermedia patients.

TL;DR: Clinicians should incite clinicians for a close follow-up and monitoring of high risk patients who are susceptible to developing priapism, due to either a cellular mechanism involving a thrombus obstructing the efferent venules of the corpora cavernosa leading to priapist, or a recently elucidated functional mechanism that causes alteration of nitric oxide response of the penis, ultimately causing priapisms.
Journal ArticleDOI

Development of a thalassemia-related thrombosis risk scoring system

TL;DR: Findings from a nationwide study of outcomes of nontrauma splenectomy for benign and malignant hematologic conditions and an analysis of the American College of Surgeons National Surgical Quality Improvement Program data show clear trends in efficacy, complications, and impact on survival and transformation.
Journal ArticleDOI

Clostridium difficile infection epidemiology and management: Comparison of results of a prospective study with a retrospective one in a reference teaching and research hospital in Northern Italy.

TL;DR: In this article, the authors developed a preventive protocol that was adopted in a hospital in 2010, and they then conducted a prospective study to investigate prevalence, incidence, and mortality of CDAD and compared the results with those of the retrospective study, evaluating adherence to preventive measures and their efficacy.
Journal ArticleDOI

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

TL;DR: Evaluating the impact of the severity of the liver iron overload on the change in myocardial T2* (mT2*) for patients receiving up to 3 years of DFX treatment in the EPIC sub-study found that there was a statistically significant difference amongst the 3 subgroups in percent increase in the mT2* that had occurred.